Positives

• Some Russian-language reviews of post-COVID neurological disorders catalogue cerebrolysin among the cognitive-rehabilitation pharmacotherapies most actively used in Eastern European post-COVID clinics, with reported improvements in cognitive clarity, focus, and mood regulation across the patient cohort Neuroscience and Behavioral Physiology.
  
  
• Patients receiving cerebrolysin in post-acute and functional neurology settings have reported improvements in cognitive clarity, focus, and mood regulation, supporting its broader exploration in Long COVID brain fog populations Nuutro.
  
  
• Cerebrolysin has been used internationally in neurology for over two decades for stroke and dementia, with patient-reported gains in attention and processing speed that may translate to the post-COVID cognitive-impairment population Nuutro.
  
  

Negatives

• Cerebrolysin is not FDA-approved in the United States and lacks robust randomized controlled trial data demonstrating major cognitive boosts in healthy people; small older volunteer studies showed only short-term EEG changes and minor memory improvements rather than a Long COVID-specific benefit. Wikipedia.
• Patients exploring cerebrolysin describe headaches as a common adverse effect, along with dizziness or lightheadedness, and note that the drug does not produce immediate cognitive improvement and may temporarily worsen brain fog during the first day or two of dosing. Innovations in Clinical Neuroscience.
• Cerebrolysin must be administered parenterally (IM or IV injection) rather than orally, creating a significant burden for Long COVID patients who would need to self-inject or arrange clinical injections over multi-week courses. Wholistic Research.

Hurdles & Side Effects

• Cerebrolysin requires IV or IM administration in a series of 10-30 daily injections per course (often repeated quarterly), is not FDA-approved in the US, and patients typically pay $1,500-$4,000 per course out of pocket through compounding pharmacies or international sources Nuutro.